ARDELYX Q3 2026 EARNINGS - ARDELYX INC

Explicit Guidance:

• FY 2026 Revenue Guidance (Ibsrella): Reaffirmed range of $350–$370 million, representing >30% annual growth at the mid-point.
• FY 2026 Revenue Guidance (Xfosa): Reaffirmed range of $110–$120 million.
• FY 2026 Operating Expenses (OpEx): Expects full-year OpEx to remain below $500 million.
• Profitability Target: Anticipates achieving operating profitability in 2027.
• Gross Margin/Net: Maintains expectation of gross profit margins >95%; blended gross-to-net rate for Q3 2026 was 31.7%, with long-term expectations in the low-to-mid 30s.
• Cash Position: Entered Q3 2026 with $285.3 million in cash and short-term investments to fund operations and pipeline.

Business-Segment Outlook:

• Ibsrella (IBSC): Full-year growth trajectory supported by all-time high demand; target to achieve $1 billion in annual revenue long-term.
• Ibsrella (CIC Expansion): Phase 3 "EXCEL" trial for Chronic Idiopathic Constipation (CIC) fully enrolled ahead of schedule; top-line results expected in H2 2027. Management views CIC as a "significantly greater" market opportunity than IBSC, anticipating label expansion to capture patients failing OTC or current prescriptions.
• Xfosa (CKD/Dialysis): Continuing to navigate complex reimbursement environment; revenue growth driven by paid prescriptions (+22% YoY in Q3) despite sequential channel buying pattern volatility.
• Sales Force & Reimbursement: Doubled Field Reimbursement Management (FRM) team; expanded sales force to increase HCP reach. Strategy focuses on transitioning patients to the Ibsrella Pharmacy Network (IPN) to improve fulfillment rates (+2–3x), faster fill times, and +1 additional refill per patient annually.
• DTC Campaign: Launched first direct-to-consumer ad on September 1st targeting >10M consumers (Netflix, Hulu, Prime Video, Disney+); early indicators show meaningful website traffic increases and high patient interest (91% would ask their doctor).

Market and Competitive Outlook:

• IBSC Market Dynamics: ~7 million annual prescriptions; >70% of patients experience persistent symptoms on current therapies; positioned as an alternative for dissatisfied IVFC patients.
• CIC Market Opportunity: Large underserved population cycling through OTC products; potential to replace current treatments for non-responders.
• Competitive Landscape: Emphasizes differentiation through symptom relief and real-world data showing reduced healthcare resource utilization (fewer visits/labs) compared to standard care.
• Channel Trends: Acknowledges sequential script volatility due to "channel mix" and "buying patterns" (e.g., -9% QoQ decline in Xfosa) but asserts underlying trends remain strong; expects continued friction in prior authorization (PA) requiring ongoing management.

Macro / Industry Outlook:

• Reimbursement Environment: Identifies payer friction and complex prior authorization landscapes as persistent headwinds across the industry.
• Payer Strategy: Anticipates increasing reliance on patient access initiatives, contracting, and rebating starting in 2027, though management will proceed "mindfully" to ensure value exchange rather than "dealing for the deal's sake."
• Regulatory/Labeling: Focus on expanding approved indications (CIC) to eliminate top-of-funnel friction; no updates expected on pediatric programs in the immediate term.

Strategic Initiatives:

• DTC Launch: First DTC campaign initiated in Q3 2026 to drive top-of-funnel demand; intends to leverage digital and AI tools to streamline prior authorization.
• Infrastructure Investment: Continued deployment of FRMs to assist HCPs with PA processes; leveraging IPN to optimize patient adherence and fulfillment.
• Pipeline Development: Heavy investment in the EXCEL Phase 3 trial (an increase in R&D OpEx from $18.1M to $25.2M QoQ) to support the 2027 launch of the CIC indication.
• Financial Discipline: Commitment to prudent expense management to maintain the path to 2027 profitability; using cash and revenue to self-fund operations.

Risks and Headwinds to Outlook:

• Reimbursement Complexity: Persistent delays in PA approvals and potential erosion of gross-to-net margins due to contracting and payer demands (expected to worsen slightly in 2027).
• Pricing/Contracting Pressure: Potential for margin erosion if aggressive rebate/contracting strategies are required to gain market access in 2027.
• Data Inaccuracy: Acknowledges potential discrepancies between projected IPN capture data and actual IVIQIA reported numbers, requiring careful interpretation of weekly trends.
• Clinical Trial Execution: Uncertainty surrounding top-line results for the EXCEL trial (CIC) in H2 2027.
• Market Volatility: Sensitivity to seasonal buying patterns and "channel mix" dynamics in the dialysis sector affecting quarterly revenue recognition.

Management Tone on the Future:

• Confidence Level: High confidence in current trajectory; management "reaffirmed" all guidance despite external volatility, citing strong fundamentals and execution.
• Strategic Patience: Views the elimination of payer friction as a "multi-threaded" process requiring time and incremental steps rather than a "magic bullet" or dramatic inflection point.
• Forward-Looking Focus: Emphasizes the transition from "commercial execution" to "building a pipeline" to create long-term value; explicitly disclaims specific forward guidance for 2027 regarding revenue targets or specific contract terms.
• Discipline: Repeated emphasis on "prudent" capital allocation and avoiding "giving away the store" in exchange for access.

Miscellaneous:

• R&D Expense Impact: Q3 R&D increase ($25.2M vs $18.1M YoY) directly attributed to the EXCEL Phase 3 trial investment.
• SG&A Expense: Maintained at ~$25M QoQ, reflecting deliberate investments in FRMs and DTC launches.
• Share-based Compensation: Included $15.1M in Q3 2026 net loss (up from $12.7M YoY), impacting non-cash expense reporting but not the cash path to profitability.